TransEnterix Ushers in New Era of Robotic Surgery with First Usage of Machine Vision Capabilities
September 23 2020 - 6:55AM
Business Wire
Intelligent Surgical Unit Enables Augmented
Intelligence on the Senhance System
TransEnterix, Inc. (NYSE American:TRXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to improve minimally invasive surgery, today announced
that Hackensack Meridian Health Pascack Valley Medical Center, a
hospital in New Jersey, successfully completed its first surgical
procedures using the Intelligent Surgical UnitTM (ISU™). The
technology previously received FDA clearance, and currently enables
machine vision capabilities on the SenhanceⓇ Surgical System. The
patients were treated by Dr. Amit Trivedi, Chair of Surgery at
Hackensack Meridian Health Pascack Valley Medical Center, and his
team in multiple general surgery procedures.
“Augmented intelligence technologies, including machine vision
and machine learning, will play an increasingly significant role in
surgery. These technologies process the image and apply
intelligence to extend the surgeon’s ability to utilize information
from the surgical field of view. We are excited to be at the
forefront of the innovation curve by developing these technologies
for surgeons and patients,” said Anthony Fernando, TransEnterix
President and CEO. “The introduction of machine vision capabilities
represents an important step in our goal to reduce variability in
surgery and improve surgical outcomes by supporting surgeon
decision making and reducing cognitive fatigue.”
The Intelligent Surgical Unit adds augmented intelligence to the
Senhance Surgical System. Currently, the ISU enables machine vision
driven control of the camera which allows the system to recognize
certain objects and locations in the surgical field, and provides
seamless sharing of the surgeon console’s view across all members
of the operating room in real-time, all the while allowing the
surgeon to maintain full control. These initial capabilities are
foundational to planned future augmented intelligence features such
as scene cognition and surgical image analytics that are expected
to further enhance the digital laparoscopic experience with
Senhance. The ISU is compatible with the global installed base of
Senhance Surgical Systems and with third-party vision systems that
are currently supported by Senhance.
“The Intelligent Surgical Unit provides me with capabilities
that I’ve never before experienced in performing laparoscopic or
robotic surgery. The system can easily recognize and track
different robotic or manual instruments to move the camera
efficiently. These capabilities make controlling visualization in
complex surgery simpler and more efficient,” said Dr. Amit Trivedi.
“In addition, the ISU enabled my surgical team to see and
experience what I was seeing on the surgeon console so they could
proactively assist me and play an active role in the Digital
Laparoscopic experience. I believe the ISU will add new benefits to
what we can do in surgery, and is the start of an era where
augmented intelligence can be integrated in real-time during an
operation to benefit the surgeon and the patient.”
About TransEnterix
At TransEnterix, Inc., we are digitizing the interface between
the surgeon and the patient to improve minimally invasive surgery
(MIS) through a new category of care called Digital Laparoscopy.
Digitizing the interface enables the use of advanced capabilities
like augmented intelligence, connectivity and robotics in
laparoscopy, and allows us to address the current clinical,
cognitive and economic shortcomings in surgery. The system features
the first machine vision system for use in robotic surgery which is
powered by the new Intelligent Surgical Unit™ (ISU™) that enables
augmented intelligence in surgery. The Senhance®️ Surgical System
brings the benefits of Digital Laparoscopy to patients around the
world while staying true to the principles of value-based
healthcare. Learn more about Digital Laparoscopy with the Senhance
Surgical System here: https://Senhance.com/. Now available for sale
in the US, the EU, Japan, and select other countries. For a
complete list of indications for use, please visit:
https://www.transenterix.com/indications-for-use/.
Forward-Looking Statements
This press release includes statements relating to the Senhance
System and the first usage of machine vision capabilities in
robotic surgery. These statements and other statements regarding
our future plans and goals constitute "forward looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, and are
intended to qualify for the safe harbor from liability established
by the Private Securities Litigation Reform Act of 1995. Such
statements are subject to risks and uncertainties that are often
difficult to predict, are beyond our control and which may cause
results to differ materially from expectations and include whether
the ISU’s augmented intelligence, machine vision and machine
learning in digital surgery will be the primary way technology can
add new value to surgical procedures and whether the ISU will add
new benefits to what can be done in surgery and is the start of an
era where augmented intelligence can be integrated in real-time
during an operation to benefit the surgeon and the patient. For a
discussion of the risks and uncertainties associated with
TransEnterix's business, please review our filings with the
Securities and Exchange Commission (SEC), including our Annual
Report on Form 10-K for the year ended December 31, 2019, filed
with the SEC on March 16, 2020 and our other filings we make with
the SEC. You are cautioned not to place undue reliance on these
forward looking statements, which are based on our expectations as
of the date of this press release and speak only as of the
origination date of this press release. We undertake no obligation
to publicly update or revise any forward-looking statement, whether
as a result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200923005174/en/
For TransEnterix, Inc. Investor Contact: Mark Klausner, +1
443-213-0501 invest@transenterix.com or Media Contact: Terri
Clevenger, +1 203-682-8297 terri.clevenger@icrinc.com
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Aug 2024 to Sep 2024
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Sep 2023 to Sep 2024